Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective.
Kittens immunized with purified native FeLV-gp70 or -gp85 envelope proteins developed ELISA, but not virus neutralizing, antibodies in their serum to both whole FeLV and FeLV-gp70. Kittens vaccinated with envelope proteins and infected with feline sarcoma virus (FeSV) developed smaller tumors than nonvaccinates, but a greater incidence of persistent retroviremia. Similarly, FeLV-gp70 and -gp85 vaccinated kittens were more apt to become persistently retroviremic following virulent FeLV challenge exposure than nonvaccinates. Kittens vaccinated with inactivated whole FeLV developed smaller tumors after FeSV inoculation and had a lower incidence of persistent retroviremia than nonvaccinates. The protective effect of inactivated whole FeLV vaccine against persistent retroviremia was also seen with FeLV challenge-exposed cats. Protection afforded by inactivated whole FeLV vaccine was not associated with virus neutralizing antibodies, although ELISA antibodies to both whole FeLV and FeLV-gp70 were induced by vaccination.
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D002371:Cat Diseases / Q000209:etiology / Q000276:immunology*; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D005354:Fibrosarcoma / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary; D006023:Glycoproteins / Q000008:administration & dosage / Q000276:immunology; D005256:Leukemia Virus, Feline / Q000276:immunology / Q000502:physiology*; D009500:Neutralization Tests; D005253:Sarcoma Viruses, Feline / Q000472:pathogenicity; D014613:Vaccines, Attenuated / Q000276:immunology; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*; D014766:Viremia / Q000209:etiology / Q000276:immunology / Q000662:veterinary*
D000914:Antibodies, Viral; D006023:Glycoproteins; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines